Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08XOT
|
||||
| Former ID |
DPR000127
|
||||
| Drug Name |
LY467711
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Neuropathic pain; Migraine [ICD9: 338, 346,780; ICD10:G43, R52, G89] | Terminated | [1] | ||
| Therapeutic Class |
Analgesics
|
||||
| Company |
Eli Lilly
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H29N5O3
|
||||
| Canonical SMILES |
CCC(C)OC(=O)C1CC2CC(CCC2CN1)OC3=CC=CC=C3C4=NNN=N4
|
||||
| InChI |
1S/C21H29N5O3/c1-3-13(2)28-21(27)18-11-15-10-16(9-8-14(15)12-22-18)29-19-7-5-4-6-17(19)20-23-25-26-24-20/h4-7,13-16,18,22H,3,8-12H2,1-2H3,(H,23,24,25,26)/t13?,14-,15+,16-,18-/m0/s1
|
||||
| InChIKey |
GUJDAZQDHPVNBE-VCGNEYLSSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Metabotropic glutamate receptor 5 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Huntington's disease | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group I pathway | |||||
| Endogenous cannabinoid signaling | |||||
| Reactome | G alpha (q) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| GPCRs, Class C Metabotropic glutamate, pheromone | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015556) | ||||
| REF 2 | Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.